TrialThe Lancet. Haematology2017

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Ruben A Mesa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.